SARS treatment. Interferon shows promise in monkeys.
Identifieur interne : 002A78 ( PubMed/Checkpoint ); précédent : 002A77; suivant : 002A79SARS treatment. Interferon shows promise in monkeys.
Auteurs : Martin EnserinkSource :
- Science (New York, N.Y.) [ 1095-9203 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (usage thérapeutique), Humains, Interféron alpha (administration et posologie), Interféron alpha (usage thérapeutique), Macaca fascicularis, Polyéthylène glycols, Poumon (anatomopathologie), Protéines recombinantes, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (anatomopathologie), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Antiviraux, Interféron alpha.
- anatomopathologie : Poumon, Syndrome respiratoire aigu sévère.
- immunologie : Virus du SRAS.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Anticorps monoclonaux, Antiviraux, Interféron alpha.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Humains, Macaca fascicularis, Polyéthylène glycols, Protéines recombinantes, Syndrome respiratoire aigu sévère, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (therapeutic use), Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Humans, Interferon alpha-2, Interferon-alpha (administration & dosage), Interferon-alpha (therapeutic use), Lung (pathology), Macaca fascicularis, Polyethylene Glycols, Recombinant Proteins, SARS Virus (drug effects), SARS Virus (immunology), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (pathology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology).
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha.
- chemical , therapeutic use : Antibodies, Monoclonal, Antiviral Agents, Interferon-alpha.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus.
- pathology : Lung, Severe Acute Respiratory Syndrome.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Humans, Interferon alpha-2, Macaca fascicularis, Polyethylene Glycols, Recombinant Proteins.
DOI: 10.1126/science.303.5662.1273a
PubMed: 14988528
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:14988528Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS treatment. Interferon shows promise in monkeys.</title><author><name sortKey="Enserink, Martin" sort="Enserink, Martin" uniqKey="Enserink M" first="Martin" last="Enserink">Martin Enserink</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:14988528</idno><idno type="pmid">14988528</idno><idno type="doi">10.1126/science.303.5662.1273a</idno><idno type="wicri:Area/PubMed/Corpus">002F36</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F36</idno><idno type="wicri:Area/PubMed/Curation">002F36</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F36</idno><idno type="wicri:Area/PubMed/Checkpoint">002A78</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002A78</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS treatment. Interferon shows promise in monkeys.</title><author><name sortKey="Enserink, Martin" sort="Enserink, Martin" uniqKey="Enserink M" first="Martin" last="Enserink">Martin Enserink</name></author></analytic><series><title level="j">Science (New York, N.Y.)</title><idno type="eISSN">1095-9203</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Humans</term><term>Interferon alpha-2</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (therapeutic use)</term><term>Lung (pathology)</term><term>Macaca fascicularis</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>SARS Virus (drug effects)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (pathology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Antiviraux (administration et posologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Humains</term><term>Interféron alpha (administration et posologie)</term><term>Interféron alpha (usage thérapeutique)</term><term>Macaca fascicularis</term><term>Polyéthylène glycols</term><term>Poumon (anatomopathologie)</term><term>Protéines recombinantes</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (anatomopathologie)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antiviral Agents</term><term>Interferon-alpha</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Poumon</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lung</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antiviraux</term><term>Interféron alpha</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Interferon alpha-2</term><term>Macaca fascicularis</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Macaca fascicularis</term><term>Polyéthylène glycols</term><term>Protéines recombinantes</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14988528</PMID><DateCompleted><Year>2004</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>303</Volume><Issue>5662</Issue><PubDate><Year>2004</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>SARS treatment. Interferon shows promise in monkeys.</ArticleTitle><Pagination><MedlinePgn>1273-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Enserink</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016433">News</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077190">Interferon alpha-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3WJQ0SDW1A</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>G8RGG88B68</RegistryNumber><NameOfSubstance UI="C417083">peginterferon alfa-2b</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q46947FE7K</RegistryNumber><NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077190" MajorTopicYN="N">Interferon alpha-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="Y">Interferon-alpha</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011092" MajorTopicYN="Y">Polyethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14988528</ArticleId><ArticleId IdType="doi">10.1126/science.303.5662.1273a</ArticleId><ArticleId IdType="pii">303/5662/1273a</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Enserink, Martin" sort="Enserink, Martin" uniqKey="Enserink M" first="Martin" last="Enserink">Martin Enserink</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A78 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002A78 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:14988528
|texte= SARS treatment. Interferon shows promise in monkeys.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:14988528" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |